Commercialization: Page 44
-
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Market Research: Data Are Driving Decisions
According to the authors of the GreenBook Blog, which provides original insight into the challenges faced by the market research industry today, there are several major trends (see related box on this page) that collectively paint a picture of an industry that is facing many challenges, but also ...
By Taren Grom • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Creating a Multichannel Marketing Approach
No one in the pharma industry who is charged with building relationships with physicians should be surprised about the increasing need to engage in the digital space with HCPs, and to provide clear, concise brand and product messages that can be easily shared across multiple channels. What might ...
By Dan Brilot • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Payer Perspectives on PROs: Now and in the Future
“Let’s talk." That’s what we said to a cross-section of health care payers to gauge how they felt about using evidence from patient reported outcome surveys (PROs) when making coverage decisions for pharmaceuticals. The input we received during our in-depth conversations provided valuable insight...
By Martha Bayliss • March 1, 2015 -
PharmaVoice Team/PharmaVoice
C-Suite: EHR/EMR
Electronic Heath Records/ Electronic Medical Records We asked C-suite executives from the EHR/EMR arena where the greatest opportunities for improvement lie and what the greatest barriers to adoption are. Rob Cosinuke Chief Marketing Officer, athenahealth President, Epocrates, an athenahealth ser...
By Taren Grom • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The Evolution Revolution Over the past couple of years, PharmaVOICE has been reporting on the industry’s move from a pill-based model to one in which the customer, or patient, is at the center. We’ve heard from analysts and thought leaders why this shift — driven by myriad factors, such as the ch...
By Taren Grom • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
UpFront
Film to Shed Light on Neurological Condition The film crew chats with Kirk J., a young stroke victim currently coping with PBA. Avanir Pharmaceuticals has begun production of The PBA Film Project, a documentary to provide an intimate look at six real people living with a little-known neuro...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
The Network
Instagram Emerging as Pharma Friendly Trending Now: Verified badges and a high number of disease state group users bring Instagram within pharma marketing reach. Instagram began offering verified badges for brands at the end of 2014. The badges are designed to make it easier for people to identi...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
What's New
Dohmen Life Science Services Acquires Siren Interactive Trending now: Holistic patient-service model complemented by rare disease expertise. Dohmen Life Science Services, a provider of outsourced business services for biopharma and medtech innovators, has acquired Siren Interactive Corp., a rar...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Top 30 Pharma Companies R&D Spending Increases Trending Now: The overall increase in R&D spending was partly due to drug makers advancing their pipeline programs into later-stage clinical trials. The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Executive appointments and promotions in the healthcare industry Pharma Pool Dr. Julie Gerberding Merck Strengthens Executive Team Merck has named Julie Gerberding, M.D., as executive VP for strategic communications, global public policy and population health. In this newly created executive comm...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Last Word
Addressing the Needs of THOSE WITH RARE DISEASES Peter Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), talks about recent orphan drug approvals. PV: 2014 was a record year for orphan drug approvals. What are your predictions for the orphan drug space for 201...
By Peter Saltonstall • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Re-Imagining the Future of the Life-sciences Industry
The pharmaceutical industry — after facing dramatic changes over the past 10 years or so — has more transformative changes ahead. With an increasingly restrictive physician landscape, an ever-changing payer market, and technological advances that are speeding processes and improving data collecti...
By Robin Robinson • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Marketing in a Digital World
As consumer use of mobile — especially smartphones — reaches critical mass, a truly integrated digital strategy is not only necessary, but positions the channel as the central port of entry for the customer experience. Back in the dawn of mobile marketing, pharma companies often viewed mobile as ...
By Robin Robinson • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Gen Y - Gen How
Whether you want to hire them or sell them a product, meeting the needs of Millennials requires new strategies. As the newest generation of healthcare consumers and employment pool, the Gen Y population — all 77 million of them — want you to know something. They want to be happy, they want to ...
By Robin Robinson • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Ireland: Set to Soar Again
The Irish pharmaceutical market has grown exponentially over the past 50 years thanks to a skilled talent pool, trusted environment, and good government incentives. The Republic of Ireland, a country of about 4.7 million people, is a member of the European Union and today ranks as one of the we...
By Kim Ribbink • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Outsourcing: Outsourcing in a New Era
Companies continue to examine new ways to optimize operations and capitalize on efficiencies through partnerships. As the industry continues to move to a more patient-centric model, which encompasses all aspects of the continuum from R&D through commercialization, CROs and other service partn...
By Taren Grom • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
A New and Better Commercial Model for Enhanced Value
By combining the expertise of a CRO with that of a contract commercial organization, an outsourced provider can help clients bring business strategy to science and scientific expertise to business. Those companies able to take strategic advantage of this new model will be better positioned to foc...
By Michael Griffith • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Dynamic Strategic Outsourcing and New Commercial Paradigms: Benefits of Changing The Fixed-to-variable Ratio
Biopharmaceutical companies’ commercial paradigms must respond to an ever-changing marketplace, with increasing demands from both payers and patients for better care, improved outcomes, more affordable therapies, and increased speed to market. In a recent interview, George Esgro, Vice President &...
By George Esgro • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharmaceutical Call Centers Build Relationships and Improve Outcomes
As communication channels expand, field-based sales representatives will be pivotal in coordinating communications with HCPs to support educational needs and ensure value is delivered no matter which channel is used. Life-sciences companies have a significant need to build relationships with heal...
By Lou Shapiro • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Cancer — Impacts Us All In 2014, there were an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the United States alone. Cancer remains the second-most common cause of death in the United States, accounting for almost one of every four deaths. While usually lumped under...
By Taren Grom • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
UpFront
The Amgen Foundation Expands Amgen Scholars Program The Amgen Scholars Program is expanding its presence with new host institutions in the United States, Europe, and, for the first time, Japan. The Amgen Scholars Program aims to inspire the next generation of innovators by providing undergraduate...
By Denise Myshko • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
From Smart Pills to Digital Medicines Markus Christen, Ph.D., Senior VP, Global Development, Proteus Digital Health, ?talks about the company’s smart pill technology, which has the potential to lead to a new therapeutic category of products: digital medicines. Digital technology is transforming j...
By Markus Christen • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
The Network
Using Digital Across the Spectrum to Improve Care Trending Now: Patients, especially millennials, are open to online healthcare engagement. NPR Study Shows Americans -Willing to Share Health Data, ?with a Caveat A new study from NPR and Truven Health Analytics of 3,000 Americans shows that there ...
By Taren Grom • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
Pharma Companies Help Shape Accenture Life Sciences Cloud for R&D Trending Now: Eisai, Merck, and Pfizer join with Accenture to build a standards-driven platform ?powered by Oracle to help simplify and speed drug development. Accenture has launched Accenture Life Sciences Cloud for R&D, w...
By Denise Myshko • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Sales, marketing, And R&D?Trends affecting the healthcare industry Pharma Companies Not Ready for Personalized Medicine Trending Now: Janssen, Roche, and Novartis are disrupters in personalized medicine and ?have demonstrated the ability to competitively reshape therapeutic areas. Leading ph...
By Denise Myshko • Jan. 1, 2015
Previous
